Cargando…

Provider experiences with relaxing restrictions on take-home medications for opioid use disorder during the COVID-19 pandemic: A qualitative systematic review

BACKGROUND: Historical restrictions on take-home medications for opioid use disorder have generated considerable debate. The COVID-19 pandemic shifted the perceived risks and benefits of daily clinic attendance and led to widespread policy reform, creating an unprecedented opportunity to explore the...

Descripción completa

Detalles Bibliográficos
Autores principales: Adams, Alison, Blawatt, Sarin, MacDonald, Scott, Finnick, Rhys, Lajeunesse, Julie, Harrison, Scott, Byres, David, Schechter, Martin T., Oviedo-Joekes, Eugenia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165059/
https://www.ncbi.nlm.nih.gov/pubmed/37182352
http://dx.doi.org/10.1016/j.drugpo.2023.104058
_version_ 1785038187141267456
author Adams, Alison
Blawatt, Sarin
MacDonald, Scott
Finnick, Rhys
Lajeunesse, Julie
Harrison, Scott
Byres, David
Schechter, Martin T.
Oviedo-Joekes, Eugenia
author_facet Adams, Alison
Blawatt, Sarin
MacDonald, Scott
Finnick, Rhys
Lajeunesse, Julie
Harrison, Scott
Byres, David
Schechter, Martin T.
Oviedo-Joekes, Eugenia
author_sort Adams, Alison
collection PubMed
description BACKGROUND: Historical restrictions on take-home medications for opioid use disorder have generated considerable debate. The COVID-19 pandemic shifted the perceived risks and benefits of daily clinic attendance and led to widespread policy reform, creating an unprecedented opportunity to explore the impact of more flexible prescribing. We conducted a qualitative systematic review to synthesize the evidence on providers’ experiences with relaxing restrictions on take-home doses of medications prescribed for opioid use disorder during the COVID-19 pandemic. METHODS: The protocol for this systematic review was registered in PROSPERO (CRD42022360589; https://www.crd.york.ac.uk/prospero/). From Sept.–Nov. 2022, we searched Medline, Embase, CINAHL, PsycInfo, Web of Science, the Cochrane Register of Controlled Trials, and the grey literature from 2020 onward. Studies were eligible for inclusion if they used qualitative methods to investigate providers’ experiences with relaxed restrictions on take-home medications for opioid use disorder during the COVID-19 pandemic. We appraised study quality using the CASP qualitative checklist and used thematic synthesis and GRADE-CERQual to synthesize the results. RESULTS: We retrieved 13 articles representing 11 studies. Six were conducted in the United States and most focused on changes to methadone treatment. Providers’ experiences with increased flexibilities around take-homes were broadly positive, despite widespread initial concern over client safety and the potential for medication misuse. For a small number of providers, concerns about diversion were a specific manifestation of more general unease with loss of control over clients and the treatment process. Most providers appreciated increased flexibilities and described them as enabling more individualized, person-centered care. CONCLUSION: Our findings support the continuation of flexibilities around take-homes and demonstrate that regulations and policies that reduce flexibility around take-homes conflict with person-centered approaches to care. Stronger guidance and support from professional regulatory agencies may help increase uptake of flexibilities around take-homes.
format Online
Article
Text
id pubmed-10165059
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-101650592023-05-08 Provider experiences with relaxing restrictions on take-home medications for opioid use disorder during the COVID-19 pandemic: A qualitative systematic review Adams, Alison Blawatt, Sarin MacDonald, Scott Finnick, Rhys Lajeunesse, Julie Harrison, Scott Byres, David Schechter, Martin T. Oviedo-Joekes, Eugenia Int J Drug Policy Review BACKGROUND: Historical restrictions on take-home medications for opioid use disorder have generated considerable debate. The COVID-19 pandemic shifted the perceived risks and benefits of daily clinic attendance and led to widespread policy reform, creating an unprecedented opportunity to explore the impact of more flexible prescribing. We conducted a qualitative systematic review to synthesize the evidence on providers’ experiences with relaxing restrictions on take-home doses of medications prescribed for opioid use disorder during the COVID-19 pandemic. METHODS: The protocol for this systematic review was registered in PROSPERO (CRD42022360589; https://www.crd.york.ac.uk/prospero/). From Sept.–Nov. 2022, we searched Medline, Embase, CINAHL, PsycInfo, Web of Science, the Cochrane Register of Controlled Trials, and the grey literature from 2020 onward. Studies were eligible for inclusion if they used qualitative methods to investigate providers’ experiences with relaxed restrictions on take-home medications for opioid use disorder during the COVID-19 pandemic. We appraised study quality using the CASP qualitative checklist and used thematic synthesis and GRADE-CERQual to synthesize the results. RESULTS: We retrieved 13 articles representing 11 studies. Six were conducted in the United States and most focused on changes to methadone treatment. Providers’ experiences with increased flexibilities around take-homes were broadly positive, despite widespread initial concern over client safety and the potential for medication misuse. For a small number of providers, concerns about diversion were a specific manifestation of more general unease with loss of control over clients and the treatment process. Most providers appreciated increased flexibilities and described them as enabling more individualized, person-centered care. CONCLUSION: Our findings support the continuation of flexibilities around take-homes and demonstrate that regulations and policies that reduce flexibility around take-homes conflict with person-centered approaches to care. Stronger guidance and support from professional regulatory agencies may help increase uptake of flexibilities around take-homes. Elsevier B.V. 2023-07 2023-05-08 /pmc/articles/PMC10165059/ /pubmed/37182352 http://dx.doi.org/10.1016/j.drugpo.2023.104058 Text en © 2023 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Review
Adams, Alison
Blawatt, Sarin
MacDonald, Scott
Finnick, Rhys
Lajeunesse, Julie
Harrison, Scott
Byres, David
Schechter, Martin T.
Oviedo-Joekes, Eugenia
Provider experiences with relaxing restrictions on take-home medications for opioid use disorder during the COVID-19 pandemic: A qualitative systematic review
title Provider experiences with relaxing restrictions on take-home medications for opioid use disorder during the COVID-19 pandemic: A qualitative systematic review
title_full Provider experiences with relaxing restrictions on take-home medications for opioid use disorder during the COVID-19 pandemic: A qualitative systematic review
title_fullStr Provider experiences with relaxing restrictions on take-home medications for opioid use disorder during the COVID-19 pandemic: A qualitative systematic review
title_full_unstemmed Provider experiences with relaxing restrictions on take-home medications for opioid use disorder during the COVID-19 pandemic: A qualitative systematic review
title_short Provider experiences with relaxing restrictions on take-home medications for opioid use disorder during the COVID-19 pandemic: A qualitative systematic review
title_sort provider experiences with relaxing restrictions on take-home medications for opioid use disorder during the covid-19 pandemic: a qualitative systematic review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165059/
https://www.ncbi.nlm.nih.gov/pubmed/37182352
http://dx.doi.org/10.1016/j.drugpo.2023.104058
work_keys_str_mv AT adamsalison providerexperienceswithrelaxingrestrictionsontakehomemedicationsforopioidusedisorderduringthecovid19pandemicaqualitativesystematicreview
AT blawattsarin providerexperienceswithrelaxingrestrictionsontakehomemedicationsforopioidusedisorderduringthecovid19pandemicaqualitativesystematicreview
AT macdonaldscott providerexperienceswithrelaxingrestrictionsontakehomemedicationsforopioidusedisorderduringthecovid19pandemicaqualitativesystematicreview
AT finnickrhys providerexperienceswithrelaxingrestrictionsontakehomemedicationsforopioidusedisorderduringthecovid19pandemicaqualitativesystematicreview
AT lajeunessejulie providerexperienceswithrelaxingrestrictionsontakehomemedicationsforopioidusedisorderduringthecovid19pandemicaqualitativesystematicreview
AT harrisonscott providerexperienceswithrelaxingrestrictionsontakehomemedicationsforopioidusedisorderduringthecovid19pandemicaqualitativesystematicreview
AT byresdavid providerexperienceswithrelaxingrestrictionsontakehomemedicationsforopioidusedisorderduringthecovid19pandemicaqualitativesystematicreview
AT schechtermartint providerexperienceswithrelaxingrestrictionsontakehomemedicationsforopioidusedisorderduringthecovid19pandemicaqualitativesystematicreview
AT oviedojoekeseugenia providerexperienceswithrelaxingrestrictionsontakehomemedicationsforopioidusedisorderduringthecovid19pandemicaqualitativesystematicreview